CN105636645A - 在肌萎缩症中的血管紧张素 - Google Patents

在肌萎缩症中的血管紧张素 Download PDF

Info

Publication number
CN105636645A
CN105636645A CN201480034275.5A CN201480034275A CN105636645A CN 105636645 A CN105636645 A CN 105636645A CN 201480034275 A CN201480034275 A CN 201480034275A CN 105636645 A CN105636645 A CN 105636645A
Authority
CN
China
Prior art keywords
angiotensin
peptide
body weight
muscular dystrophy
muscular atrophy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480034275.5A
Other languages
English (en)
Chinese (zh)
Inventor
R·萨巴瓦尔
M·沙普洛
R·弗兰克林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Iowa Research Foundation
Constant Therapeutics LLC
Original Assignee
University of Iowa Research Foundation
Tarix Orphan LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Iowa Research Foundation, Tarix Orphan LLC filed Critical University of Iowa Research Foundation
Publication of CN105636645A publication Critical patent/CN105636645A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201480034275.5A 2013-04-19 2014-04-18 在肌萎缩症中的血管紧张素 Pending CN105636645A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361813929P 2013-04-19 2013-04-19
US61/813,929 2013-04-19
US201361818307P 2013-05-01 2013-05-01
US61/818,307 2013-05-01
PCT/US2014/034615 WO2014189634A1 (en) 2013-04-19 2014-04-18 Angiotensins in muscular dystrophy

Publications (1)

Publication Number Publication Date
CN105636645A true CN105636645A (zh) 2016-06-01

Family

ID=51933952

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480034275.5A Pending CN105636645A (zh) 2013-04-19 2014-04-18 在肌萎缩症中的血管紧张素

Country Status (11)

Country Link
US (2) US20160074464A1 (enExample)
EP (1) EP2986341A4 (enExample)
JP (1) JP2016522178A (enExample)
KR (1) KR20160026855A (enExample)
CN (1) CN105636645A (enExample)
AU (1) AU2014269028A1 (enExample)
BR (1) BR112015026286A2 (enExample)
CA (1) CA2909002A1 (enExample)
MX (1) MX2015014668A (enExample)
RU (1) RU2015141336A (enExample)
WO (1) WO2014189634A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2016152088A (ru) 2014-07-17 2018-08-21 Юниверсити Оф Саузерн Калифорния Способы, соединения и композиции для лечения заболеваний опорно-двигательного аппарата
US10973869B2 (en) 2017-05-17 2021-04-13 Constant Therapeutics Llc Methods of treating cardiomyopathy associated with genetic disorders
KR102885525B1 (ko) * 2018-11-06 2025-11-13 엣지와이즈 테라퓨틱스, 인크. 피리다지논 화합물 및 이의 용도
SMT202300355T1 (it) 2018-11-06 2024-01-10 Edgewise Therapeutics Inc Composti di piridazinone e loro usi
WO2020097258A1 (en) 2018-11-06 2020-05-14 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
EP4473968A3 (en) 2020-05-13 2025-03-26 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
CN118680926B (zh) * 2024-07-30 2024-12-20 北京市糖尿病研究所(北京市糖尿病防治办公室) Mas受体激动剂在制备预防或治疗多囊卵巢综合征的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196452A1 (en) * 2007-01-26 2010-08-05 Universidade Federal De Minas Gerais- Ufmg Pharmaceutical compositions and methods for treating erectile dysfunction
CN102164614A (zh) * 2008-09-12 2011-08-24 柏林夏洛蒂医科大学 Ang-(1-7) 受体激动剂在急性肺损伤中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU78601A (sh) * 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
US9186295B2 (en) * 2011-10-25 2015-11-17 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
BR132012028005E2 (pt) * 2012-10-31 2014-11-18 Univ Minas Gerais Composições farmacêuticas contendo um agonista do receptor mas para o tratamento de doenças degenerativas musculares.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196452A1 (en) * 2007-01-26 2010-08-05 Universidade Federal De Minas Gerais- Ufmg Pharmaceutical compositions and methods for treating erectile dysfunction
CN102164614A (zh) * 2008-09-12 2011-08-24 柏林夏洛蒂医科大学 Ang-(1-7) 受体激动剂在急性肺损伤中的用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GUILIAN SUN等: "Intramuscular renin-angiotensin system is activated in human muscular dystrophy，40-48", 《JOURNAL OF THE NEUROLOGICAL SCIENCE》 *
LEON D. KLUSKENS等: "Angiotensin-(1-7) with Thioether Bridge: An Angiotensin-Converting Enzyme-Resistant, Potent Angiotensin-(1-7) Analog", 《JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS》 *
RASNA SABHARWAL，MARK W CHAPLEAU: "Angiotensin-[1-7] Infusion Reduces Skeletal Muscle Fibrosis and Restores Locomotor Activity and Sympathovagal Balance in a Mouse Model of Muscular Dystrophy，Abstract 398", 《HYPERTENSION》 *

Also Published As

Publication number Publication date
EP2986341A4 (en) 2016-11-30
US20160074464A1 (en) 2016-03-17
EP2986341A1 (en) 2016-02-24
JP2016522178A (ja) 2016-07-28
CA2909002A1 (en) 2014-11-27
RU2015141336A (ru) 2017-05-22
MX2015014668A (es) 2016-06-30
US20180221433A1 (en) 2018-08-09
BR112015026286A2 (pt) 2017-10-10
WO2014189634A1 (en) 2014-11-27
KR20160026855A (ko) 2016-03-09
AU2014269028A1 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
US20180221433A1 (en) Angiotensins in muscular dystrophy
CN104394878A (zh) 用于治疗周围血管疾病的组合物和方法
RU2661109C2 (ru) Ангиотензин в лечении состояний головного мозга
US20180050079A1 (en) Angiotensin peptides in treating marfan syndrome and related disorders
US8846601B2 (en) Melanocortin receptor-specific peptides
JP2018530590A (ja) 表皮水疱症の処置のための方法及び組成物
US9333233B2 (en) Methods and compositions for the delayed treatment of stroke
KR20150065736A (ko) 안지오텐신의 경구 제형
US8557958B1 (en) Compositions and methods for treatment of diabetes
US20160296591A1 (en) Compositions and methods for treatment of bdnf-related conditions
WO2016112247A1 (en) Methods and compositions for the treatment of amyotrophic lateral sclerosis
US9133241B2 (en) Peptide compositions
US10973869B2 (en) Methods of treating cardiomyopathy associated with genetic disorders
WO2015057403A2 (en) Compositions and methods for treatment of inflammatory bowel disease
TW202539635A (zh) 用於治療天疱瘡或類天疱瘡疾病的經改良方法及組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160601